Scarica l'app Stockscreener
9.05
5.97%
0.51
Dopo l'orario di chiusura:
9.05
Precedente Chiudi:
$8.54
Aprire:
$8.69
Volume 24 ore:
1.34M
Relative Volume:
1.57
Capitalizzazione di mercato:
$466.95M
Reddito:
$676.80M
Utile/perdita netta:
$-8.60M
Rapporto P/E:
-31.99
EPS:
-0.2829
Flusso di cassa netto:
$135.40M
1 W Prestazione:
+9.96%
1M Prestazione:
+9.96%
6M Prestazione:
-12.48%
1 anno Prestazione:
+82.83%
Intervallo 1D:
$8.67
$9.5401
Intervallo di 1 settimana:
$7.5318
$9.5401
Portata 52W:
$4.71
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, TEVA, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.05 | 440.63M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director DeGolyer sells $129,993 in shares By Investing.com - Investing.com India
Emergent BioSolutions director Dayal sells $115,610 in stock - Investing.com
Emergent BioSolutions director DeGolyer sells $129,993 in shares - Investing.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock - Investing.com
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives new grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options - Stock Titan
Director Marvin White (NYSE: EBS) receives RSU and stock option awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options for board service - Stock Titan
Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options in annual award - Stock Titan
Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
MSN Money - MSN
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses - Sahm
Emergent BioSolutions Earnings Call Highlights Turnaround Momentum - The Globe and Mail
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer LINDAHL RICHARD S - Moomoo
Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer PAPA JOSEPH C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Perl Jessica - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Hartzel William - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Lowry Simon C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Glessner Coleen - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved - MarketBeat
Emergent BioSolutions Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:EBS) 2026-05-02 - Seeking Alpha
Emergent BioSolutions Q1 2026 Financial Results: Earnings, Revenue, and Key Risk Factors Explained - Minichart
Emergent BioSolutions Posts Weak Q1 Results Amid Turnaround - The Globe and Mail
Emergent BioSolutions (EBS) SVP awarded 100,111 restricted stock units under amended plan - Stock Titan
Emergent BioSolutions (EBS) awards 100,111 RSUs to R&D CMO - Stock Titan
Emergent BioSolutions (NYSE: EBS) awards 100,111 RSUs to EVP - Stock Titan
Emergent BioSolutions (EBS) CFO receives 162,680 restricted stock units - Stock Titan
Emergent BioSolutions (EBS) SVP awarded 104,282 restricted stock units - Stock Titan
SVP at Emergent BioSolutions (NYSE: EBS) receives 100,111 RSUs - Stock Titan
Emergent BioSolutions (NYSE: EBS) CEO gets 187,708 RSUs over 3 years - Stock Titan
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Emergent (EBS) Q1 2026 Earnings Transcript - The Globe and Mail
Emergent Biosolutions Q1 2026 earnings preview - MSN
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Emergent Biosolutions Q1 Earnings Call Highlights - MarketBeat
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights - GuruFocus
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround - Investing.com Australia
Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround By Investing.com - Investing.com South Africa
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):